We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

HospiMedica

Download Mobile App
Recent News AI Critical Care Surgical Techniques Patient Care Health IT Point of Care Business Focus

Majority of IV Infusion Errors Linked to Clinical Practice

By HospiMedica International staff writers
Posted on 20 Mar 2016
More than half of intravenous (IV) infusion medications contained errors, with majority linked to deviations in hospital policy, according to a new study.

Researchers at Brigham and Women's Hospital (Boston, MA, USA), Concord Hospital (NH, USA), and other institutions conducted a study in ten hospitals in the United States to investigate the types and frequency of IV medication errors associated with smart pumps. Data were collected using a prospective point prevalence approach to capture errors associated with 1,164 smart pump IV administrations to 478 patients, with concurrent evaluation of their potential for harm.

The results showed that of the observed infusions, 699 (60%) had one or more errors associated with their administration, but relatively few of these errors were potentially harmful. The most predominant errors were associated with violations of hospital infusion policy, and included the administration of unauthorized medications, bypassing the smart pump, wrong rate of infusion, labelling errors, and bypassing the integrated drug library.

The researchers suggested that most of these mistakes could be prevented if closed-loop systems, in which the smart pumps are automatically programed with a medication order using the patient’s electronic health record (EHR), were implemented as policy. This would necessitate that a nurse verify the information on the smart pump and accept the data, including drug name, infusion rate, volume, and concentration, before the infusion could begin. The study was published on February 23, 2016, in BMJ Quality & Safety.

“Since these errors are not directly related to the use of smart pumps, these finding suggest that smart pump technology alone cannot fully prevent errors associated with intravenous infusions,” concluded lead author Kumiko Schnock, MD, of Brigham and Women's Hospital, and colleagues. “The results of this study will be useful in developing interventions to eliminate errors in the intravenous medication administration process.”

Smart infusion pumps were developed to reduce adverse drug events and medication administration errors through built-in safety features, such as built-in drug libraries and dose error reduction systems. According to a national survey conducted by the American Society of Health-System Pharmacists (Bethesda, MD, USA), in 2012 77% of hospitals in the United States use smart pump technology.

Related Links:

Brigham and Women's Hospital
Concord Hospital
American Society of Health-System Pharmacists


Gold Member
SARS‑CoV‑2/Flu A/Flu B/RSV Sample-To-Answer Test
SARS‑CoV‑2/Flu A/Flu B/RSV Cartridge (CE-IVD)
Gold Member
POC Blood Gas Analyzer
Stat Profile Prime Plus
New
CMS
Dixion Central Monitoring Station
New
Electrically Operated Patient Lifter
SVL 205

Channels

Patient Care

view channel
Image: The revolutionary automatic IV-Line flushing device set for launch in the EU and US in 2026 (Photo courtesy of Droplet IV)

Revolutionary Automatic IV-Line Flushing Device to Enhance Infusion Care

More than 80% of in-hospital patients receive intravenous (IV) therapy. Every dose of IV medicine delivered in a small volume (<250 mL) infusion bag should be followed by subsequent flushing to ensure... Read more

Business

view channel
Image: A research collaboration aims to further advance findings in human genomics research in cardiovascular diseases (Photo courtesy of 123RF)

Bayer and Broad Institute Extend Research Collaboration to Develop New Cardiovascular Therapies

A research collaboration will focus on the joint discovery of novel therapeutic approaches based on findings in human genomics research related to cardiovascular diseases. Bayer (Berlin, Germany) and... Read more